Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency.
Proof of principle is provided for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants by normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice.